The Mutational Landscape of Prostate Cancer Christopher E. Barbieri, Chris H. Bangma, Anders Bjartell, James W.F. Catto, Zoran Culig, Henrik Grönberg, Jun Luo, Tapio Visakorpi, Mark A. Rubin  European Urology  Volume 64, Issue 4, Pages 567-576 (October 2013) DOI: 10.1016/j.eururo.2013.05.029 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 Molecular classification of prostate cancer (PCa). (a) The majority of primary PCas harbor ETS rearrangements, most commonly as TMPRSS2-ERG fusions. The PTEN and TP53 tumor suppressors are deleted or mutated in 20–40% of primary PCa, with significant overlap with each other and ETS rearrangements. SPOP mutations, which occur in approximately 10% of PCas, are mutually exclusive with ETS rearrangements and relatively lack PTEN deletions and other lesions but are associated with deletions of CHD1. (b) Metastatic tumors have a significant increase in lesions in PTEN and other PI3K pathway components and an increase in genomic aberrations; in addition, mutations and amplifications of AR emerge, mostly in cancers treated with androgen-deprivation therapy. European Urology 2013 64, 567-576DOI: (10.1016/j.eururo.2013.05.029) Copyright © 2013 European Association of Urology Terms and Conditions